首页> 美国卫生研究院文献>other >Poly(2-oxazoline) based Micelles with High Capacity for 3rd Generation Taxoids: preparation in vitro and in vivo evaluation
【2h】

Poly(2-oxazoline) based Micelles with High Capacity for 3rd Generation Taxoids: preparation in vitro and in vivo evaluation

机译:基于聚(2-恶唑啉)的胶束具有高容量可用于第三代紫杉醇:制备体内和体外评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The clinically and commercially successful taxanes, paclitaxel and docetaxel suffer from two major drawbacks, namely their very low aqueous solubility and the risk of developing resistance. Here, we present a method that overcomes both drawbacks in a very simple manner. We formulated 3rd generation taxoids, able to avoid common drug resistance mechanisms with doubly amphiphilic poly(2-oxazoline)s (POx), a safe and highly efficient polymer for the formulation of extremely hydrophobic drugs. We found excellent solubilization of different 3rd generation taxoids irrespective of the drug's chemical structures with essentially quantitative drug loading and final drug to polymer ratios around unity. The small, highly loaded micelles with a hydrodynamic diameter of less than 100 nm are excellently suited for parenteral administration. Moreover, a selected formulation with the taxoid SB-T-1214 is about one to two orders of magnitude more active in vitro than paclitaxel in the multidrug resistant breast cancer cell line LCC6-MDR. In contrast, in wild-type LCC6, no difference was observed. Using a q4d x 4 dosing regimen, we also found that POx/SB-T-1214 significantly inhibits the growth of LCC6-MDR orthotropic tumors, outperforming commercial paclitaxel drug Taxol and Cremophor EL formulated SB-T-1214.
机译:临床上和商业上成功的紫杉烷类,紫杉醇和多西紫杉醇具有两个主要缺点,即它们的水溶性很低以及产生抗药性的风险。在这里,我们提出了一种以非常简单的方式克服两个缺点的方法。我们配制了3代staxoids,能够避免双亲两性聚(2-恶唑啉)(POx)的常见耐药机制,而POx是一种安全高效的高度疏水性药物配方聚合物。我们发现,不同的3 rd 类紫杉醇具有出色的增溶作用,而与药物的化学结构无关,基本上具有定量的药物载量和最终药物与聚合物的比率约为1。流体动力学直径小于100 nm的小,高负荷胶束非常适合肠胃外给药。此外,在多药耐药性乳腺癌细胞LCC6-MDR中,具有紫杉醇SB-T-1214的选定制剂在体外的活性比紫杉醇高约一到两个数量级。相反,在野生型LCC6中,未观察到差异。使用q4d x 4给药方案,我们还发现POx / SB-T-1214显着抑制LCC6-MDR正交异性肿瘤的生长,优于商业紫杉醇药物紫杉醇和Cremophor EL配制的SB-T-1214。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号